Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 6/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.74 |
| ▸ | PGR | P06401 | 5/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | MLNR | O43193 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | SHBG | P04278 | 4/20 | 0.70 |
| ▸ | AR | P10275 | 4/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27048175 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| SCHEMBL29766827 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| SCHEMBL260024 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| SCHEMBL13941349 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| SCHEMBL12666930 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| SCHEMBL8853536 | 0.91 | LMNA (0.72) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| SCHEMBL8937171 | 0.91 | LMNA (0.72) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| Medroxyprogesterone Acetate SCHEMBL10949732 | 0.91 | NR3C1 (0.88) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| SCHEMBL11810769 | 0.91 | AR (0.63) | SMN1; SMN2LMNANR3C1CYP3A4PGR | |
| SCHEMBL11810794 | 0.91 | AR (0.63) | SMN1; SMN2LMNANR3C1CYP3A4PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1835 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319100-A1 | ANTI-TUMOR COMBINED PREPARATION COMPRISING HYDROXYPROGESTERONE CAPROATE AND USE THEREOF | SHENZHEN EVERGREEN THERAPEUTICS CO., LTD. (CN) | 2025-10-16 | — | — | US | claimed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| CN-119173283-A | Radiopharmaceutical complexes targeting prostate specific membrane antigen and combinations thereof | 拜耳股份有限公司 | 2024-12-20 | — | — | CN | claimed |
| EP-4309658-A1 | ANTI-TUMOR COMBINED PREPARATION COMPRISING HYDROXYPROGESTERONE CAPROATE AND USE THEREOF | Shenzhen Evergreen Therapeutics Co., Ltd. (CN) | 2024-01-24 | — | — | EP | claimed |
| CN-117285583-A | Preparation method of steroid medicine modified by oxidation at 6-position or 10-position | 中国科学院上海药物研究所 | 2023-12-26 | — | — | CN | claimed |
| US-20230181599-A1 | PROGESTOGEN FORMULATIONS AND USES THEREOF | SHENZHEN EVERGREEN THERAPEUTICS CO LTD (CN) | 2023-06-15 | — | — | US | claimed |
| US-20220008334-A1 | GASTRIC RETENTIVE DEVICES | CLEXIO BIOSCIENCES LTD. (IL) | 2022-01-13 | — | — | US | claimed |
| CN-110618225-B | Method for constructing database to detect hormone | 吉林出入境检验检疫局检验检疫技术中心 | 2021-11-26 | — | — | CN | claimed |
| US-20210361674-A1 | Treating Auto-Immune and Auto-Inflammatory Diseases | SHENZHEN EVERGREEN THERAPEUTICS CO., LTD. (CN) | 2021-11-25 | — | — | US | claimed |
| WO-2021226390-A1 | PROGESTOGEN FORMULATIONS AND USES THEREOF | SHENZHEN EVERGREEN THERAPEUTICS CO., LTD. (CN) | 2021-11-11 | — | — | WO | claimed |
| WO-2000042955-A1 | DRUG DOSAGE UNIT FOR BUCCAL ADMINISTRATION OF STEROIDAL ACTIVE AGENTS | PLACE VIRGIL A (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2000042942-A2 | BUCCAL DRUG DELIVERY SYSTEM FOR USE IN MALE CONTRACEPTION | PLACE VIRGIL A (US) | 2000-07-27 | — | — | WO | claimed |
| US-5906830-A | POLYMER, DRUG MIXTURE | CYGNUS, INC. (US) | 1999-05-25 | — | — | US | claimed |
| US-5902603-A | INCLUDING A PERMEABILITY ENHANCER ABSORBED THEREIN; HIGHER LOADS; HIGH CAPACITY AND FLUX; CROSSLINKED POLYURETHANE REACTED WITH WATER; ADMINISTERING STEROIDS AND OLANZAPINE | CYGNUS, INC. (US) | 1999-05-11 | — | — | US | claimed |
| US-5023088-A | Drug delivery dispenser | ALZA CORPORATION (US) | 1991-06-11 | — | — | US | claimed |
| US-4588529-A | Mercury removal process | THE UPJOHN COMPANY (US) | 1986-05-13 | — | — | US | claimed |
| US-4154748-A | Phosphate catalyzed acylation of steroidal tertiary alcohols | THE UPJOHN COMPANY (US) | 1979-05-15 | — | — | US | claimed |
| US-4016270-A | Method for treating dysmenorrhea with a uterine therapeutic system | ALZA CORPORATION (US) | 1977-04-05 | — | — | US | claimed |
| US-4014988-A | Method for treating hypermenorrhea with uterine therapeutic system | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-3993072-A | Microporous drug delivery device | ALZA CORPORATION (US) | 1976-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210361674-A1 | Treating Auto-Immune and Auto-Inflammatory Diseases | IL17A, IL23R, IL15 | SMN1; SMN2 4443/4885LMNA 4156/4885NR3C1 6/4885 |
| US-20230181599-A1 | PROGESTOGEN FORMULATIONS AND USES THEREOF | SHBG, PGR, CYP17A1 | SMN1; SMN2 1289/4885LMNA 847/4885NR3C1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.